Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an ...

Investing.com -- Cassava Sciences, Inc. (NASDAQ: SAVA )宣布获得其候选药物simufilam的一项治疗方法专利独家许可后，公司股价上涨7%。该专利涉及罕见神经发育障碍相关癫痫的潜在治疗方法，包括结节性硬化症（TSC）。

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company's announcement of securing an exclusive license to a method of treatment patent f ...

在2024年，全球制药行业经历了诸多挫折，许多备受期待的药物在临床试验中“夭折”。这些失败不仅给药企带来了巨大的经济损失，也凸显了药物研发的复杂性和不确定性。下面，让我们一起来看看去年一整年较为突出的十起失败案例： ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

《自然》杂志最近的一份分析显示，从2014年至2024年，全球近60%撤稿的学术文章作者来自中国，中国地方医院尤其成为“学术不端”的重灾区。中国有超过20000篇科研文章遭到撤稿，撤稿率约为0.3%，是全球平均水平的三倍。全球打假的“科学侦探”们组成 ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment ...

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

《自然》杂志最近的一份分析显示，从2014年至2024年，全球近60%撤稿的学术文章作者来自中国，中国地方医院尤其成为“学术不端”的重灾区。中国有超过20000篇科研文章遭到撤稿，撤稿率约为0.3%，是全球平均水平的三倍。

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer’s disease, the most common form of dementia that afflicts tens of millions of people ...